• Onglyza Medical Record Review & Outsourcing Services

Onglyza (saxagliptin) belongs to drug class dipeptidyl peptidase-4 (DPP-4) inhibitor; it was approved by the U.S. Food and Drug Administration (FDA) on July 31, 2009. The drug was initially developed by Bristol-Myers Squibb; this was followed by AstraZeneca joining with Bristol-Myers Squibb in 2007 to co-develop the product and collaborating on the marketing front as well. Onglyza is prescribed for the treatment of Type-2 diabetes to be used along with diet and exercise to lower blood sugar in adults. Saxagliptin helps the pancreas to secrete more insulin and stops the liver from making excess sugar. Onglyza effectively controls the blood sugar without causing any weight fluctuations.

Studies conducted showed that people on Onglyza medication had a higher risk of pancreatic cancer and increased risk of hospitalization due to heart failure; thus, the medication has ended up causing more harm than benefit to diabetic patients.

Serious Alleged Injuries may include:

  • Pancreatic cancer
  • Acute pancreatitis inflammation)
  • Severe Joint Pain
  • Thyroid cancer
  • Heart failure
  • Death

FDA Safety Warnings:

  • March 14, 2013: The FDA issued a drug safety communication that it was evaluating unpublished findings by researchers that linked Onglyza and other diabetes drugs with pancreatitis and cellular changes called “pancreatic duct metaplasia.”

  • February 11, 2014:  The FDA issued another drug safety communication, warning of an increased rate of hospitalization for saxagliptin users due to heart failure compared to nonusers of the drug.

  • April 5, 2016: The FDA issued Onglyza warning stating the addition of a heart disease and heart failure warning to the drug’s label. This warning was particularly important for people who were heart patients or had kidney problems. The SAVOR clinical studies further supported the warnings stating that there was a 27% increased risk of heart failure linked to Onglyza.

  • February 2017: AstraZeneca announced that the FDA gave an approval to Qtern, a once-daily oral fixed dose medication for treating type 2 diabetes in adults. Qtern is a combination of 5 mg of DPP-4 inhibitor saxagliptin (Onglyza) and 10 mg of SGLT2 inhibitor dapagliflozin (Forxiga/Farxiga).

Legal Updates:

Defendants: Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals, and McKesson Corporation are the defendants named in this litigation.

Defense Law Firm: Bristol-Myers Squibb and McKesson are represented by Phyllis A. Jones of Covington & Burling LLP. AstraZeneca is represented by Donald F. Zimmer Jr. of King & Spalding LLP.

Allegations: All lawsuits revolve around the common allegation that the drug maker knew or should have known about the link between Onglyza and heart failure for years, yet failed to adequately warn users and the medical community.

Plaintiffs' Steering Committee:

  • Raymond Boucher - Boucher LLP

  • Frank M. Petosa - MORGAN & MORGAN


  • Jerome P. Prather  - GARMER & PRATHER


  • Steven Teppler - ABBOTT LAW GROUP

  • Jennifer Lenze - LENZE LAWYERS

  • Matthew L. White - GRAY & WHITELAW

  • Kim Loutey - KENNERLY LOUTEY

Lawsuit Status:

  • February 2018: MDL No.: 2809-In Re: Onglyza and Kombiglyze XR Products Liability Litigation was established for coordinated pretrial proceedings in the U.S. District Court for the Eastern District of Kentucky under District Judge Karen K. Caldwell. Approximately 80 Onglyza and Kombiglyze lawsuits were a part of this docket.

  • June 2018: As per the JPML's report on pending MDL dockets, nearly  200 lawsuits remain pending in the Eastern District of Kentucky for the drugs Onglyza and Kombiglyze XR.

  • November 2018: Judge Caldwell announced the bifurcation of Onglyza heart failure cases by establishing two phases for discovery, with the first focusing on general causation and whether plaintiffs can establish that the diabetes drug causes heart failure.

  • Onglyza lawsuits alleging heart failure whose plaintiffs are California residents have remained in state superior court under Judge Curtis E.A. Karnow—specifically Case No. CJC-16-004909 .

Important Verdicts & Settlements

Proposed bellwether trials in October 2020


  • Usage of Onglyza in Medical and Pharmacy Records
  • Duration of Onglyza usage in medical records
  • Proof of injury and Treatment provided for injuries

Medical Record Review and claim validation of Onglyza case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.



Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...


NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...



CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...


CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...


NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

International Yoga Day - Image - Neural IT
International Yoga Day celebrated at Neural IT to bring physical and emotional health for our tea
MTMP April 2019
Neural IT shared presence with Mike Papantonio at the spectacular 3-day conferenc
1st Quarter 2019 ‘Rewards & Recognition Program
Neural IT celebrated Employee Appreciation Day on April 5, 2019, by rewarding its star performers

Latest Tweets